Looking beyond the current treatment paradigms for metabolic disorders.
We are committed to developing innovative therapies for metabolic disorders.
Our current pipeline consists of two investigational drugs for the treatment of diabetes. Metabolic diseases represent one of the great public health challenges of our time. We see new opportunities on the horizon to improve the lives of patients with these conditions.
Metavant Sciences has formed important alliances with companies
who share our commitment to develop innovative drug candidates into medicines
that will change the lives of patients with cardiometabolic diseases.